Depo-Provera Brain Tumor Lawsuit Lawyers

If you received Depo-Provera injections for years and were later diagnosed with a meningioma, pseudotumor cerebri, or another serious neurologic condition, you are not alone — and the emerging science suggests you were never properly warned. Pfizer’s injectable contraceptive, marketed for decades as a set-it-and-forget-it alternative to the pill, has now been linked in peer-reviewed studies to a 5- to 6-fold increased risk of intracranial meningioma with long-term use. More than 3,490 women have filed brain tumor lawsuits in the federal multidistrict litigation consolidated before a judge in Pensacola, and the case count grows each month.

Neumann Law Group is accepting Depo-Provera injury cases nationwide. We are screening clients for meningioma brain tumors, pseudotumor cerebri / idiopathic intracranial hypertension, and a limited number of secondary injury categories tied to long-term progestin exposure. If you think Depo-Provera may have caused your diagnosis, our attorneys can evaluate your case at no cost, coordinate the neuro-oncology and neuro-ophthalmology experts needed to build it, and position it properly within or alongside MDL 3140.

What is Depo-Provera and why are women filing lawsuits?

Depo-Provera (depot medroxyprogesterone acetate, or DMPA) is a long-acting progestin-only contraceptive injection, typically given every three months. Pfizer, along with Pharmacia & Upjohn, Greenstone, and other distributors, has marketed the drug since the 1990s as a convenient alternative to daily oral contraceptives. Tens of millions of women worldwide have received it, often for years at a time.

The lawsuits center on a simple allegation: Pfizer knew, or should have known, that long-term Depo-Provera use significantly raised the risk of meningioma brain tumors, but failed to adequately warn U.S. patients and doctors. A 2024 study published in the BMJ analyzing French national health data found that women using injectable progestogens like DMPA for more than a year had approximately 5.6 times the odds of developing an intracranial meningioma compared to non-users. A 2025 U.S. study in JAMA Neurology confirmed the signal, with particularly elevated risk in women over age 31 and those with four or more years of exposure.

Critically, Pfizer added meningioma warnings to Depo-Provera labeling in other countries years before doing so in the United States. The FDA did not approve a U.S. label change warning of meningioma risk until December 2025 — decades after the first scientific concerns surfaced in the 1990s.

What injuries are connected to Depo-Provera?

The Depo-Provera litigation has centered on two primary neurologic injuries, with several secondary categories under investigation.

Intracranial meningioma

Meningiomas are tumors that grow in the membranes surrounding the brain and spinal cord. Most are technically non-cancerous, but that classification is misleading — meningiomas can grow for years without symptoms and, when they cause problems, can be devastating. Depending on location and size, a meningioma can trigger seizures, chronic headaches, vision loss from optic nerve compression, hearing loss, memory deficits, personality changes, and focal weakness. Treatment often requires craniotomy, stereotactic radiosurgery, or lifelong anticonvulsant medication. Some patients are left with permanent neurologic deficits after surgery.

Meningiomas are hormone-sensitive tumors, which is why hormonal exposures like long-term Depo-Provera use have drawn scientific scrutiny.

Pseudotumor cerebri / idiopathic intracranial hypertension

A second category of Depo-Provera injury lawsuits involves pseudotumor cerebri, also called idiopathic intracranial hypertension (IIH) — a condition of dangerously elevated pressure around the brain. Symptoms include severe headaches, pulsatile tinnitus, transient visual obscurations, double vision, papilledema (swelling of the optic nerve), and progressive vision loss. Treatment often requires repeated lumbar punctures to drain cerebrospinal fluid, placement of a CSF shunt, or optic nerve sheath fenestration surgery. Untreated IIH can cause permanent blindness.

Secondary injury categories

Our firm is also evaluating a limited number of cases involving premature osteoporosis with fragility fractures in long-term Depo-Provera users (a risk Pfizer has acknowledged with a boxed warning for years), and select breast cancer cases where Depo-Provera was the dominant hormonal exposure, in light of emerging data on progestogen-only contraception and breast cancer risk.

What is the Depo-Provera MDL and where does it stand?

In February 2025, the Judicial Panel on Multidistrict Litigation consolidated federal Depo-Provera lawsuits into MDL 3140 — In re: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation — in the U.S. District Court for the Northern District of Florida. The Honorable M. Casey Rodgers, an experienced mass-tort jurist, presides.

As of April 2026, more than 3,490 cases are pending in MDL 3140 according to JPML statistics, with plaintiffs’ leadership reporting a substantial inventory of additional unfiled claims under investigation. Case counts update monthly; current figures are published on the MDL docket. The litigation is moving into its most consequential phase:

• Five bellwether cases have been selected to serve as representative trials. The first, Blonski v. Pfizer, is currently scheduled for December 7, 2026.
• Daubert hearings on general causation — where Judge Rodgers will decide whether plaintiffs’ scientific experts can testify that Depo-Provera causes meningioma — are scheduled for June 24–26, 2026.
• Pfizer’s federal preemption defense — the manufacturer’s argument that FDA regulations shield it from failure-to-warn claims — is fully briefed and awaiting ruling. The December 2025 FDA-approved label change adding a meningioma warning has substantially weakened this defense.
• Monthly case management conferences run through December 2026.

Bellwether outcomes historically drive settlement negotiations. A plaintiff verdict in December 2026 would put significant pressure on Pfizer to resolve the thousands of pending and anticipated claims globally.

Does Michigan’s drug manufacturer immunity statute affect my case?

If you live in Michigan, you may have read about the state’s former drug-manufacturer immunity statute, MCL 600.2946(5). That subsection — once the strictest in the nation — was repealed by Senate Bill 410, signed in December 2023 and effective February 13, 2024. For Depo-Provera claims that accrue after that date, Michigan claimants face no special immunity hurdle at all.

For claims that accrued before February 13, 2024, the prior version of the statute and its fraud-on-the-FDA exception may still apply. That exception strips manufacturers of immunity when they intentionally withheld material information from the FDA, and the drug would not have been approved (or approval would have been withdrawn) had the information been submitted. That is precisely the allegation driving MDL 3140: that Pfizer possessed scientific evidence of elevated meningioma risk for decades, added warnings to Depo-Provera labeling in foreign markets, but concealed or minimized that same information from U.S. regulators. The MDL discovery record now developing directly supports the exception.

We assess every Michigan claim against the date of injury and the operative version of the statute, and we coordinate fraud-exception arguments at the MDL level, where the analysis applies uniformly across state lines.

Who qualifies to file a Depo-Provera lawsuit?

Intake criteria in a mass tort evolve as litigation matures, and not every Depo-Provera user with a neurologic diagnosis will qualify. That said, the cases our firm is actively screening generally share the following characteristics:

Exposure profile. A documented history of Depo-Provera injections, typically for at least one year of continuous use and often longer (three to five years or more). Long-term use beyond age 30 to 35 substantially strengthens a claim. Pharmacy records, OB/GYN chart notes referencing DMPA or “depo shot,” and insurance claim data can all establish exposure.

Qualifying diagnosis. Either (1) an intracranial meningioma confirmed by MRI or CT imaging, ideally with pathology if surgical resection occurred; or (2) a diagnosis of pseudotumor cerebri or idiopathic intracranial hypertension with objective neuro-ophthalmology findings such as papilledema, elevated opening pressure on lumbar puncture, or documented visual field loss.

Temporal relationship. Diagnosis occurring during or after a meaningful period of Depo-Provera exposure — generally at least six months after the first injection, and often years into use.

No dominant alternative cause. Cases are stronger where other meningioma risk factors can be excluded, such as prior cranial radiation, neurofibromatosis type 2, or significant high-dose hormone replacement therapy.

If your situation does not fit this profile exactly, we still encourage you to call. The science on progestin-only contraceptives is evolving, and the MDL’s case acceptance criteria have broadened as new evidence emerges.

What evidence do I need to preserve?

The sooner you begin preserving evidence, the stronger your case will be. At a minimum, start gathering the following:

Pharmacy and injection records. Every Depo-Provera administration date matters. If your injections were given at an OB/GYN office, family medicine clinic, or public health clinic, the relevant chart notes and billing records should document each dose. Pharmacy logs, even from years ago, can often be retrieved through records requests.

Imaging. MRI and CT scans confirming the meningioma — including the original radiology reports and, where possible, the actual DICOM images — are the backbone of a meningioma case. For IIH cases, neuro-ophthalmology records documenting papilledema, visual field testing, and lumbar puncture opening pressures are similarly essential.

Surgical and pathology records. If you underwent a craniotomy, debulking, radiosurgery, CSF shunt placement, or any other invasive procedure, the operative reports and pathology results directly establish the severity of injury and damages.

Treatment and damages documentation. Records of ongoing anticonvulsant use, cognitive or physical therapy, missed work, disability applications, and out-of-pocket medical expenses all factor into case valuation.

We handle record retrieval for our clients, but preserving what you have now — including old insurance cards, prescription bottles, and appointment calendars — makes the process faster and more thorough.

Why work with Neumann Law Group on a Depo-Provera case?

Our firm has been investigating Depo-Provera claims since the MDL’s formation and is actively litigating cases nationwide, with a focus on catastrophic neurologic injury, significant permanent visual impairment, brain surgery, and wrongful death. Kelly Neumann and our team coordinate with neuro-oncology, neurology, and neuro-ophthalmology experts to reconstruct exposure histories and document the full scope of injury for each client. We also handle a broader dangerous drug and medical device practice, including active matters involving Ozempic and Mounjaro gastroparesis claims, Tepezza hearing loss lawsuits, Elmiron vision loss cases, and Taxotere injury litigation. You can see the full scope of our pharmaceutical work on our dangerous drugs practice page, and our broader product liability and personal injury practices for context on how these claims fit within our firm’s work.

We accept Depo-Provera cases on a contingency basis. You owe nothing unless we recover for you.

Talk to a Depo-Provera brain tumor lawyer today

If you or someone you love was diagnosed with a meningioma, pseudotumor cerebri, or another serious condition after long-term Depo-Provera use, do not wait to get legal advice. Statutes of limitations can be short, and evidence gets harder to recover the longer you wait. Call Neumann Law Group at (800) 525-6386 for a free, confidential consultation. Our attorneys can evaluate your case, explain where it fits within MDL 3140, and start preserving the medical records and imaging evidence you’ll need. We represent clients nationwide from offices in Michigan, Massachusetts, California, and New York.

Frequently asked questions about Depo-Provera brain tumor lawsuits

Q: How much is a Depo-Provera lawsuit worth?

A: No global settlement has been reached, and individual case values cannot be reliably predicted before bellwether trials. Case values depend on injury severity, treatment history, duration of Depo-Provera use, and strength of causation evidence. Bellwether trial outcomes expected in late 2026 will be the first meaningful data point on case values. We do not project specific dollar ranges before evaluating a client’s records — an honest assessment requires reviewing your medical records, exposure history, and damages.

Q: Is the Depo-Provera lawsuit a class action?

A: No. The federal Depo-Provera cases are consolidated in a multidistrict litigation (MDL 3140), not a certified class action. Each plaintiff retains her own individual case, and any settlement is based on the specific facts of her injury and exposure — not an equal share divided among thousands of women.

Q: How long do I have to file a Depo-Provera lawsuit?

A: Statutes of limitations vary by state, typically ranging from two to four years from the date of diagnosis or from the date you reasonably could have connected the diagnosis to Depo-Provera use. Many states apply a discovery rule that can extend the deadline. Because the meningioma–Depo link was not widely publicized until recently, many potential claimants still have time — but the window is closing, and you should speak with an attorney quickly.

Q: I used generic medroxyprogesterone acetate, not brand-name Depo-Provera. Can I still file?

A: Possibly. The MDL addresses both brand-name Depo-Provera and generic DMPA injections from manufacturers including Pharmacia & Upjohn, Greenstone, and others. Generic-only cases can face additional legal hurdles around preemption, but they are not automatically excluded. We evaluate generic cases on their facts.

Q: What if my family member died from a Depo-Provera-related brain tumor?

A: Wrongful death claims can be pursued on behalf of the deceased’s estate. These cases often involve additional categories of damages including loss of companionship and loss of financial support. Our firm handles Depo-Provera wrongful death matters as part of the MDL and in coordination with state-level wrongful death procedures.

Q: Should I stop taking Depo-Provera?

A: That is a decision to make with your doctor, not your lawyer. Do not stop any prescribed medication without medical guidance. If you are currently using Depo-Provera and are concerned about meningioma risk, talk to your OB/GYN about the updated FDA labeling and whether continued use is appropriate for you.